ADB-FUBINACA (ADMB-FUBINACA) is a
designer drug identified in
synthetic cannabis blends in Japan in 2013.
In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the
Drug Enforcement Administration
The Drug Enforcement Administration (DEA) is a Federal law enforcement in the United States, United States federal law enforcement agency under the U.S. Department of Justice tasked with combating illicit Illegal drug trade, drug trafficking a ...
.
The name is an acronym for N-(1-Amino-3,3-Dimethyl-1-oxoButan-2-yl)-1-(4-FlUoroBenzyl)-1H-INdAzole-3-CarboxAmide.
The (''S'')-enantiomer of ADB-FUBINACA is described in a 2009
Pfizer patent
A patent is a type of intellectual property that gives its owner the legal right to exclude others from making, using, or selling an invention for a limited period of time in exchange for publishing an sufficiency of disclosure, enabling discl ...
and has been reported to be a potent
agonist
An agonist is a chemical that activates a Receptor (biochemistry), receptor to produce a biological response. Receptors are Cell (biology), cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an R ...
of the
CB1 receptor and the
CB2 receptor with
EC50 values of 1.2 nM and 3.5 nM, respectively.
[ ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a ''tert''-butyl group.
An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.
]
Side effects
One death through coronary arterial thrombosis has been linked to ADB-FUBINACA intoxication.
Metabolism
Twenty-three ADB-FUBINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Major metabolic pathways were alkyl and indazole hydroxylation, terminal amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation.
Legality
In the United States, ADB-FUBINACA is a Schedule I controlled substance.
See also
* 5F-AB-PINACA
* 5F-ADB
* 5F-AMB
* 5F-APINACA
* AB-CHFUPYCA
* AB-PINACA
* ADB-BINACA
* ADB-CHMINACA
* ADB-PINACA
* ADBICA
* ADSB-FUB-187
* APINACA
* MDMB-CHMICA
* MDMB-FUBINACA
* PF-03550096
* PX-3
References
{{Cannabinoids
Cannabinoids
Designer drugs
4-Fluorophenyl compounds
Indazolecarboxamides
Tert-butyl compounds